ADP is an important platelet agonist causing shape change and aggregation required for physiological hemostasis. We recently demonstrated the existence of two distinct G protein-coupled ADP receptors on platelets, one coupled to phospholipase C, P2Y1, and the other to inhibition of adenylyl cyclase, P2T AC . In this study, using specific antagonists for these two receptors, we demonstrated that concomitant intracellular signaling from both the P2T AC and P2Y1 receptors is essential for ADP-induced platelet aggregation. Inhibition of signaling through either receptor, by specific antagonists, is sufficient to block ADP-induced platelet aggregation. Furthermore, signaling through the P2T AC receptor could be replaced by activation of ␣ 2A -adrenergic receptors. On the other hand, activation of serotonin receptors supplements signaling through the P2Y1 receptor. Moreover, this mechanism of ADP-induced platelet aggregation could be mimicked by coactivation of two non-ADP receptors coupled to G i and G q , neither of which can cause platelet aggregation by itself. We propose that platelet aggregation results from concomitant signaling from both the G i and G q , a mechanism by which G protein-coupled receptors elicit a physiological response.ADP is the first small molecular weight platelet agonist to be identified (1). When stimulated with ADP, platelets undergo shape change, release granule contents, and produce thromboxane A 2 (2, 3). In addition, ADP activates the fibrinogen receptor, causing platelets to bind fibrinogen and aggregate (2, 3). The receptors through which extracellular nucleotides elicit physiological responses have been classified as P2 receptors and are divided into P2X ligand-gated ion channels and P2Y G protein-coupled receptors (4). These receptor subtypes are numbered in the order of cloning, and to date 7 subtypes of P2X receptors and 10 subtypes of P2Y receptors have been cloned (5, 6). Sage and coworkers (7) recently demonstrated a P2X receptor in platelets and proposed that this receptor is the P2X1 receptor subtype mediating rapid calcium influx. We have provided evidence for two distinct G protein-coupled ADP receptors, one coupled to the inhibition of adenylyl cyclase, the P2T AC receptor, and the other coupled to the activation of phospholipase C, the P2Y1 receptor, in human platelets (8,9). Several compounds, including ARL 66096, ticlopidine, and clopidogrel, have been utilized to block ADPinduced inhibition of adenylyl cyclase and subsequent platelet aggregation both in vitro and in vivo (3,8), suggesting that the P2T AC receptor mediates ADP-induced platelet aggregation.Here, we delineate the role of the three ADP receptors, the P2T AC , P2Y1, and P2X1 receptors, in ADP-induced human platelet aggregation and demonstrate that some agonistinduced physiological responses may require simultaneous activation of multiple receptor subtypes by the same agonist, resulting in converging signal transduction pathways leading to a physiological response.